No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice

Scandinavian Cardiovascular Journal

Volumn 36, Issue 6, 2002, Pages 362-367

  Olesen, Mette ^a   Kwong, Elizabeth ^b   Meztli, Arguello ^b   Kontny, Frederic ^c   Seljeflot, Ingebjörg ^c   Arnesen, Harald ^c   Lyngdorf, Line ^a   Falk, Erling ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

ApoE mice; Atherosclerosis; COX inhibitors; MF Tricyclic; Sulindac

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; CYCLOOXYGENASE 2 INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MF TRICYCLIC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; ROFECOXIB; S 18886; SULINDAC; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG SELECTIVITY; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; STATISTICAL ANALYSIS;

ALGORITHMS; ANALYSIS OF VARIANCE; ANIMALS; AORTA, THORACIC; AORTIC DISEASES; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FURANS; MALE; MICE; MICE, INBRED C57BL; SULINDAC;

EID: 12244282459     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/140174302762659094     Document Type: Article

References (32)

1. Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 1995; 33: 179-207.
2. Bazan N, Botting J, Vane J. New targets in inflammation. Inhibitors of COX-2 or adhesion molecules. London: Kluwer Academic and William Harvey Press, 1996.
3. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-314.
4. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117: 776-783.
5. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999; 354: 2106-2111.
6. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
7. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 646-655.
8. Schönbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291.
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
11. Cayette AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 1724-1728.
12. Reis ED, Roque M, Dansky H, et al. Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2000; 97: 12764-12769.
13. Topper JN, Cai J, Falb D, Gimbrone MAJ. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996: 93: 10417-10422.
14. Zembowicz A, Jones SL, Wu KK. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest 1995; 96: 1688-1692.
15. Traub O, Berk BC. Laminar shear stress: Mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 1998; 18: 677-685.
16. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999: 85: 199-207.
17. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995; 75: 3A-10A.
18. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987; 68: 231-240.
19. Dansky HM, Charlton SA, Sikes JL, et al. Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 1960-1968.
20. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 1997; 18: 1001-1006.
21. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996: 56: 2556-2560.
22. Jalbert G, Castonguay A. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Letters 1992; 66: 21-28.
23. Beazer-Barclay Y, Levy DB, Moser AR, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996; 17: 1757-1760.
24. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6: 1024-1028.
25. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
26. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-140.
27. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-482.
28. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698-701.
29. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-277.
30. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
31. Praticò D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001; 98(6): 3358-3363.
32. Ray WA, Stein MC, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of coronary heart disease: An observational cohort study. Lancet 2002; 359: 118-123.